News, Articles & Media

Caldera Health appoints Robert Mitchell as CEO

160318 Rob Mitchell, CEO Caldera Health

Wednesday 23rd March 2016 – Caldera Health has appointed Robert (Rob) Mitchell as Chief Executive Officer to manage overall operations of the company and to drive commercialisation of its gene-based prostate cancer diagnostic tests.

New Zealand-born, Rob is a highly experienced senior executive, with over 30 years in leadership roles for major global international pharmaceutical businesses. He has started and built commercial operations in Asia Pacific (New Zealand, Australia, India, Hong Kong), and headed global product strategy for Roche and The Medicines Company.

His most recent experience includes ongoing product development, approval and launches in infectious disease care with the Medicines Company (2011-2015), where he served as Senior Vice President, Head of Asia Pacific, based in Auckland, then as Senior Vice President, Global Innovation Group Leader – Infectious Disease, based in New Jersey. Before that he spent eighteen years with Roche, starting in sales and marketing in New Zealand and Australia, then held successive positions as Managing Director of Roche Products (NZ), General Manager, Roche Thailand and Head of Global Product Strategy, Virology for F Hoffman La Roche in California.

Read the full announcement here.

Read the announcement in NBR, Voxy, or BioSpace.

Cancer – The Cost of a Life

Friday 13th November 2015 – The New Zealand Herald investigates controversies in cancer testing and treatment and reports on the moving stories of people afflicted with cancer.  In the fifth and final part of this series, Herald health reporter Martin Johnston turns his attention to prostate cancer, and touches on Caldera’s diagnostic test.

“Caldera Health has … confirmed a panel of gene biomarkers for use in an affordable diagnostic test which … gives significantly better accuracy in terms of sensitivity and specificity than the PSA test,” the company says.

Read the full NZ Herald article here

Kiwi biotech company using genetic testing to diagnose prostate cancer

development of a new prostate cancer test based on gene sequencing technology that could replace the inaccurate and outdated PSA blood test currently in use.

kristen_labHuman genome sequencing has sure come a long way, baby. The Human Genome Project, started way back in 1990, took 13 years to sequence the first human genome and cost a hefty $3 billion. Fast forward to today, and that same process can be performed in 24 hours and costs less than $1000.

But when it comes to hot-button ethical issues, they don’t come much hotter than the ethics of DNA sequencing. The subject quickly brings to mind uneasy visions of dystopian futures where the value of human life is reduced to the value of its DNA, where ‘geonism’, or discrimination based on genetic predisposition, is the norm.

That, however, is hardly the full picture when it comes to the perils and potential of Next-Gen Sequencing (NGS). Because on the other side of that problematic coin is the ability of Next Generation Sequencers to diagnose life threatening illnesses hyper-accurately and on a massive scale, allowing early intervention and treatment of otherwise intractable illnesses.

That’s the space which New Zealand biotech company Caldera Health is currently exploring, identifying biomarkers and developing sophisticated software diagnostic tools for revealing prostate cancers in men. The company is using Next-Gen Sequencing to identify and measure multiple different genetic markers that occur in prostate cancers, enabling medical staff to make more informed diagnoses and better decisions around treatment options.

Read the full Idealog article here

September 2015 Newsletter to Shareholders

Read the September 2015 Newsletter for news on the following:

  • The Quarterly Review of Scientific Progress, including first data on the accuracy of Caldera’s diagnostic text, the move to automation of the test, and an update on development of Caldera’s urine prostate cancer test
  • Caldera’s Business Information document, outlining the business plan for 2016
  • The Annual Meeting of Shareholders in late October

Caldera Health asks men to give biopsy sample to help prove prostate cancer test

Fiona Rotherham reports in NBR on Caldera’s seeking biopsy sample from Kiwi men to help prove it’s prostate cancer test.


Graham Watt

Friday 18th September 2015 – Caldera Health, a New Zealand biotech company working on a gene-sequencing replacement for the world’s most widely used prostate cancer test, is seeking more biopsy sample from Kiwi men to help prove its concept.

Caldera managing director Graham Watt said he wants at least 50 samples by the end of the year though would eventually like to build up to at least 200 to help prove the credibility of its proprietary gene-sequencing test.

The medical diagnostic firm has been receiving a few samples by working in conjunction with Auckland urologists, but Watt said it’s not sufficient for its needs and is now asking me throughout New Zealand to also give their permission for the company to be sent a slither of their biopsy sample when they’re presenting with possible prostate cancer.

Read the full NBR article here

Read the article here

Keith Hudson joins Caldera Health as Director of Research and Development

NBR notes Dr Keith Hudson’s appointment


Dr Keith Hudson

Monday 18 May 2015
– Prostate cancer diagnostics company, Caldera Health, has appointed Dr Keith Hudson as director of research and development.

Keith holds a PhD in immunology from the University of Auckland (1993) and spent five years conducting postdoctoral research at the University of Oxford then the University of Birmingham. He returned to New Zealand in 1998 and worked for Genesis Research and Development, leading a research programme which resulted in several patent applications and received in excess of NZ $6 million dollars in government funding. As Chief Scientific Officer, Cartesian Group, Keith was also instrumental in developing bioinformatics software that turned genomic DNA information into useable gene sequences using a patented pattern search technology. The initiative was subsequently spu

n out into a US analytical software company.

Read the full NBR article here




Caldera close to global breakthrough on new prostate cancer test, seeks new investors

Jonathan Underhill reports in NBR on Caldera’s work on a gene-sequencing replacement for the world’s most widely used prostate cancer test.

Jim caldera2211030www

Caldera Health founder Jim Watson

Monday 18 May, 2015 – Caldera Health, a New Zealand biotech company working on a gene-sequencing replacement for the world’s most widely used prostate cancer test, is seeking new investors to complete a $2 million capital raising to finish clinical studies and put the research in front of potential commercial partners.

Auckland-based Caldera has attracted $5.93 million of investment since being incorporated in 2009, made up of $5.4 million from investors including New Image Group founder Graeme Clegg, Stephen Tindall’s K One W One, the government’s NZ Venture Investment Fund, and about $568,000 from Callaghan Innovation and its predecessors. It has raised about $1.1 million of the $2 million sought in its latest offer of 2.5 million shares at 80c apiece. Each share comes with a ‘stapled’ option to buy another share at that price by 2017. Investors need to put in a minimum of $750,000.

Read the full NBR article here

NZ biotech firm makes giant strides in cancer fight

ComputerWorld New Zealand‘s Randal Jackson speaks with Caldera’s Graham Watt and Kristen Chalmet


13 May 2015– A privately owned New Zealand biotech company has made huge progress in developing a replacement for the PSA prostate cancer test.

At present, there are 100 million PSA tests conducted worldwide each year but the test reliability suffers from false negative and false positive results with PSA testing costing global health systems around US$2 billion annually.

Caldera Ltd was established in 2010 as a molecular diagnostic development company. Prostate cancer is its first target, though the current development work has the potential, eventually, to target all cancers.

Breast cancer would be be the next target, says managing director Graham Watt.

Read the full Computerworld New Zealand article here

May 2015 Newsletter to Shareholders

Read the May 2015 Newsletter for news on the following:

  • The appointment of a new Director of Research and Development
  • Our recent project review,
  • The R&D growth grant we received from Callaghan Innovation
  • Migrating our accounting system to the cloud
  • Two further staff appointments.

This newsletter also contains a third article on prostate cancer from Dr Jim Watson.

Offer of Equity Securities in Caldera Health Limited

Caldera is raising capital by way of an offer of Equity Securities in Caldera Health Limited.

The offer is made without disclosure under Part 3 of the Financial Markets Conduct Act 2013, in reliance upon exclusions in clauses 3, 4, and 5 of Schedule 1 to the Act.

Read the Company’s notice sent to the Financial Markets Authority under the Financial Markets Conduct Act 2013  here.